New Genetic Signatures Identify Sensitive Breast Cancers

This site is intended for healthcare professionals

New Genetic Signatures Identify Platinum-Sensitive Breast Cancers

Author:

Key Summary:

  • New biomarkers identified potential platinum sensitivity in triple-negative breast cancer.
  • DNA repair signatures identified patients missed by existing deficiency testing.
  • Combining biomarkers could improve selection for platinum-based chemotherapy.

NEW research suggests that DNA repair deficiency biomarkers could help identify patients with triple-negative breast cancer (TNBC) who are more likely to respond to platinum-based chemotherapy. The findings indicate that testing for nucleotide excision repair (NER) deficiency could identify additional patients who may benefit from platinum treatment, beyond those detected through existing homologous recombination deficiency (HRD) testing.

Identifying Alternative DNA Repair Deficiencies

Platinum-based chemotherapy can increase pathological complete response rates in TNBC when compared with non-platinum neoadjuvant treatment. However, its potential toxicity highlights the importance of identifying patients most likely to benefit.

HRD has been investigated as a marker of platinum sensitivity, but existing testing has demonstrated only modest predictive ability in clinical trials. Researchers therefore explored NER deficiency as an alternative biomarker. This DNA repair mechanism had previously been linked to platinum sensitivity in bladder cancer.

The team applied an ERCC2mut score, developed using bladder cancers with inactivating ERCC2 mutations, to assess potential NER deficiency in breast cancer.

Biomarkers Identified Different Patient Groups

In the Cancer Genome Atlas breast cancer cohort of 943 cases, 4.7% showed evidence of NER deficiency without concurrent HRD.

Among 50 patients with TNBC who received cisplatin, both the ERCC2mut score and HRDetect were associated with pathological response (p=0.0077 and p=0.036, respectively). However, the biomarkers identified largely different groups of patients, suggesting that relying on HRD testing alone could overlook some individuals who may respond to platinum treatment.

In a separate trial involving 54 patients treated with cisplatin and 45 treated with paclitaxel, multiple NER deficiency-associated mutational signatures were significantly associated with treatment response in the cisplatin group, but not in the paclitaxel group.

Towards More Personalised Treatment Selection

The findings suggest that NER deficiency-associated mutational signatures could help identify a subset of patients with platinum-sensitive TNBC who may not be identified through conventional HRD testing.

Combining biomarkers that assess different DNA repair pathways could therefore improve the prediction of platinum response and support more personalised treatment selection. This approach may also help clinicians avoid exposing patients unlikely to benefit to the potential toxicity of platinum-based chemotherapy.

Further validation will be important to establish how these biomarkers could be incorporated into clinical decision-making. Nevertheless, the results highlight the potential value of assessing multiple DNA repair mechanisms when identifying patients most likely to benefit from platinum-based treatment.

Reference

Sztupinszki Z et al. Nucleotide excision repair deficiency identified by mutational signatures is associated with cisplatin response in triple-negative breast cancer. Npj Breast Cancer. 2026; DOI:https://doi.org/10.1038/s41523-026-01080-2.

Featured image: Zurnalis on Adobe Stock.

 

Adobe Stock

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.